Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7340–7347. doi: 10.1158/1078-0432.CCR-08-0642

Figure 4. Synergistic activity of PS-341 and NK84 on ovarian cancer cells is dependent upon level of metabolic activity.

Figure 4

A, Immunoblot analysis of the levels of poly-ubiquitinated proteins in cyclohexamide-exposed (24h) ES-2 ovarian cancer cells. Equal loading was verified by using an antibody directed against β-actin. B, ES-2 ovarian cancer cells pre-exposed to 0, 1 or 5 mg/ml CHX (24 hours) subsequently received treatment with of PS-341 (1nM) and NK84 (5 μM) or mock treatment. Cell viability was as evaluated by XTT assay after 24 hours of treatment. Percentage of viable cells is relative to mock-treated control cells is presented. ** P < 0.02. Error bars indicate ± SD. C, proliferation rate of confluent (+) or sub-confluent (−) ES-2 and TOV-21G ovarian cancer cell lines was measured by XTT assay. Each assay was performed in triplicate. Shown are bars ± SD of proliferative activity measured in terms of optical density at 450 nm on each given day. D, cell viability of ES-2 and TOV-21G ovarian cancer cell lines was evaluated by XTT assay in sub-confluent (−) versus confluent (+) cultures in the presence of PS-341 1nM and NK84 5 μM. Percentage of viable cells is relative to mock-treated control cells. ***P < 0.001. Error bars indicate ± SD.